Swedish biotech startup MyCural Therapeutics has been selected as a Top 100 startup, securing an opportunity to pitch on stage at TECHARENA 2025 , Scandinavia’s premier tech and business event. The recognition highlights the company’s groundbreaking work in developing novel cancer therapies targeting MYC-driven cancers — one of the most challenging areas in oncology.
Advancing Cancer Treatment Through Innovation
Founded by cancer researchers from Karolinska Institutet, Linköping University, and Uppsala University, MyCural Therapeutics is pioneering a new approach to targeting the MYC oncoprotein — a key driver of many aggressive cancers. The company has identified small molecule binders that selectively inhibit MYC in tumor cell lines and cancer models, a breakthrough that could lead to life-saving treatments for high-risk cancer patients.
“Our mission is to develop innovative therapies for patients with MYC-driven cancers, where treatment options remain limited. This recognition at TECHARENA 2025 is a fantastic opportunity to showcase our work and engage with potential partners who share our vision for the future of oncology,” — MyCural Therapeutics.
A Prestigious Stage at TECHARENA 2025
Taking place on February 20–21 at Strawberry Arena, Stockholm, TECHARENA 2025 will gather 12,000 business leaders, investors, and industry pioneers to explore the theme: “Becoming the Best in the World.” MyCural’s participation provides a platform to connect with global stakeholders, seek investment opportunities, and accelerate its drug development efforts.
An Open Call for Collaboration
As the event approaches, MyCural Therapeutics is inviting investors, biotech innovators, and pharmaceutical partners to connect and explore collaborations that could drive the next generation of cancer treatments.
✉️Are you attending TECHARENA 2025? MyCural welcomes discussions on partnerships and investment opportunities—reach out to schedule a meeting. For more information, visit www.mycural.com or connect with us on LinkedIn.
